273 related articles for article (PubMed ID: 29032022)
1. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e71-e73. PubMed ID: 29032022
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
3. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
5. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
Khoury HJ; Bixby DL
Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
Kim DD; Lee H; Kamel-Reid S; Lipton JH
Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
[TBL] [Abstract][Full Text] [Related]
10. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
12. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Lipton JH
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
[TBL] [Abstract][Full Text] [Related]
13. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
Zulbaran-Rojas A; Lin HK; Shi Q; Williams LA; George B; Garcia-Manero G; Jabbour E; O'Brien S; Ravandi F; Wierda W; Estrov Z; Borthakur G; Kadia T; Cleeland C; Cortes JE; Kantarjian H
Cancer Med; 2018 Nov; 7(11):5457-5469. PubMed ID: 30318751
[TBL] [Abstract][Full Text] [Related]
14. Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.
Iliakis T; Papadopoulou V; Diamantopoulos PT; Panayiotidis P; Zervakis K; Giannakopoulou N; Tilimidos G; Angelopoulou M; Siakantaris MP; Pangalis G; Mantzourani M; Variami E; Viniou NA
Anticancer Res; 2013 Aug; 33(8):3509-14. PubMed ID: 23898127
[TBL] [Abstract][Full Text] [Related]
15. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Radich JP; Kopecky KJ; Appelbaum FR; Kamel-Reid S; Stock W; Malnassy G; Paietta E; Wadleigh M; Larson RA; Emanuel P; Tallman M; Lipton J; Turner AR; Deininger M; Druker BJ
Blood; 2012 Nov; 120(19):3898-905. PubMed ID: 22915637
[TBL] [Abstract][Full Text] [Related]
17. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
20. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]